Leveraging collateral sensitivity to counteract the evolution of bacteriophage resistance in bacteria

Abstract

The escalating antibiotic resistance crisis poses a major global health threat. Bacteriophage therapy offers a promising alternative for combating multidrug-resistant infections. However, bacterial resistance to phages remains a significant hurdle. Innovative strategies are needed to overcome this challenge. In this study, we developed a phage cocktail based on our phage library, consisting of three phages that suppressed phage resistance of carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKp). This cocktail capitalized on dual instances of collateral sensitivity, thereby constraining the evolution of phage resistance. The first-layered collateral sensitivity arose from overlapping coverage between capsular polysaccharide (CPS) and lipopolysaccharide (LPS), rendering the bacteria resistant to CPS-binding phages but more susceptible to LPS-binding phages. The second-layered collateral sensitivity resulted from an O serotype switch (from O1 to O2), causing resistance to O1 antigen-binding phages but increasing susceptibility to phages that target the O2 antigen. This dual-layered collateral sensitivity phage cocktail effectively mitigated infection caused by CR-hvKp in mice. Our research highlights the importance of the collateral sensitivity mechanism in counteracting the evolution of phage resistance and offers a sophisticated strategy for configuring phage cocktails to eliminate bacterial resistance.

Keywords

antibiotic resistance / bacteriophage (phage) cocktails / collateral sensitivity / evolution / Klebsiella pneumoniae

References

[1] Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic Era. Clin Microbiol Rev. 2019; 32: e00066-18.

[2] Dion MB, Oechslin F, Moineau S. Phage diversity, genomics and phylogeny. Nat Rev Microbiol. 2020; 18: 125-138.

[3] Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: from biological mechanisms to future directions. Cell. 2023; 186: 17-31.

[4] Hatfull GF, Dedrick RM, Schooley RT. Phage therapy for antibiotic-resistant bacterial infections. Annu Rev Med. 2022; 73: 197-211.

[5] Bertozzi Silva J, Storms Z, Sauvageau D. Host receptors for bacteriophage adsorption. FEMS Microbiol Lett. 2016; 363: fnw002.

[6] Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol. 2010; 8: 317-327.

[7] Hesse S, Rajaure M, Wall E, Johnson J, Bliskovsky V, Gottesman S, et al. Phage resistance in multidrug-resistant Klebsiella pneumoniae ST258 evolves via diverse mutations that culminate in impaired adsorption. mBio. 2020; 11: e02530-19.

[8] Gao D, Ji H, Wang L, Li X, Hu D, Zhao J, et al. Fitness trade-offs in phage cocktail-resistant Salmonella enterica serovar enteritidis results in increased antibiotic susceptibility and reduced virulence. Microbiol Spectr. 2022; 10: e0291422.

[9] Imamovic L, Ellabaan MMH, Dantas Machado AM, Citterio L, Wulff T, Molin S, et al. Drug-driven phenotypic convergence supports rational treatment strategies of chronic infections. Cell. 2018; 172: 121-134.e14.

[10] Liu DY, Phillips L, Wilson DM, Fulton KM, Twine SM, Wong A, et al. Collateral sensitivity profiling in drug-resistant Escherichia coli identifies natural products suppressing cephalosporin resistance. Nat Commun. 2023; 14: 1976.

[11] Li Q, Chen S, Zhu K, Huang X, Huang Y, Shen Z, et al. Collateral sensitivity to pleuromutilins in vancomycin-resistant Enterococcus faecium. Nat Commun. 2022; 13: 1888.

[12] Efferth T, Saeed MEM, Kadioglu O, Seo EJ, Shirooie S, Mbaveng AT, et al. Collateral sensitivity of natural products in drug-resistant cancer cells. Biotech Adv. 2020; 38: 107342.

[13] Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, et al. Exploiting temporal collateral sensitivity in tumor clonal evolution. Cell. 2016; 165: 234-246.

[14] Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev. 2019; 32: e00001-19.

[15] Follador R, Heinz E, Wyres KL, Ellington MJ, Kowarik M, Holt KE, et al. The diversity of Klebsiella pneumoniae surface polysaccharides. Microb Genom. 2016; 2: e000073.

[16] Tang N, Hu J, Zhao Y, Song Y, Wang C, Zhang G, et al. In vivo evolution of carbapenem resistance in hypervirulent Klebsiella pneumoniae in a patient undergoing long-term treatment. J Antimicrob Chemother. 2022; 77: 531-533.

[17] Liu L, Lou N, Liang Q, Xiao W, Teng G, Ma J, et al. Chasing the landscape for intrahospital transmission and evolution of hypervirulent carbapenem-resistant Klebsiella pneumoniae. Sci Bull. 2023; 68: 3027-3047.

[18] Yang J, Li Y, Tang N, Li J, Zhou J, Lu S, et al. The human gut serves as a reservoir of hypervirulent Klebsiella pneumoniae. Gut Microbes. 2022; 14: 2114739.

[19] Gorrie CL, Mirčeta M, Wick RR, Edwards DJ, Thomson NR, Strugnell RA, et al. Gastrointestinal carriage is a major reservoir of Klebsiella pneumoniae infection in intensive care patients. Clin Infect Dis. 2017; 65: 208-215.

[20] Calderon-Gonzalez R, Lee A, Lopez-Campos G, Hancock SJ, Sa-Pessoa J, Dumigan A, et al. Modelling the gastrointestinal carriage of Klebsiella pneumoniae infections. mBio. 2023; 14: e0312122.

[21] Federici S, Kredo-Russo S, Valdés-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell. 2022; 185: 2879-2898.e24.

[22] Hesse S, Malachowa N, Porter AR, Freedman B, Kobayashi SD, Gardner DJ, et al. Bacteriophage treatment rescues mice infected with multidrug-resistant Klebsiella pneumoniae ST258. mBio. 2021; 12: e00034-21.

[23] He J, Shi Q, Chen Z, Zhang W, Lan P, Xu Q, et al. Opposite evolution of pathogenicity driven by in vivo wzc and wcaJ mutations in ST11-KL64 carbapenem-resistant Klebsiella pneumoniae. Drug Resist Updates. 2023; 66: 100891.

[24] Patel KB, Toh E, Fernandez XB, Hanuszkiewicz A, Hardy GG, Brun YV, et al. Functional characterization of UDP-glucose:undecaprenyl-phosphate glucose-1-phosphate transferases of Escherichia coli and Caulobacter crescentus. J Bacteriol. 2012; 194: 2646-2657.

[25] Kneidinger B, Marolda C, Graninger M, Zamyatina A, McArthur F, Kosma P, et al. Biosynthesis pathway of ADP-l-glycero-β-d-manno-heptose in Escherichia coli. J Bacteriol. 2002; 184: 363-369.

[26] Holmes CL, Smith SN, Gurczynski SJ, Severin GB, Unverdorben LV, Vornhagen J, et al. The ADP-heptose biosynthesis enzyme GmhB is a conserved gram-negative bacteremia fitness factor. Infect Immun. 2022; 90: e0022422.

[27] Chiu SF, Teng KW, Wang PC, Chung HY, Wang CJ, Cheng HC, et al. Helicobacter pylori GmhB enzyme involved in ADP-heptose biosynthesis pathway is essential for lipopolysaccharide biosynthesis and bacterial virulence. Virulence. 2021; 12: 1610-1628.

[28] Kelly SD, Clarke BR, Ovchinnikova OG, Sweeney RP, Williamson ML, Lowary TL, et al. Klebsiella pneumoniae O1 and O2ac antigens provide prototypes for an unusual strategy for polysaccharide antigen diversification. J Biol Chem. 2019; 294: 10863-10876.

[29] Clarke BR, Ovchinnikova OG, Kelly SD, Williamson ML, Butler JE, Liu B, et al. Molecular basis for the structural diversity in serogroup O2-antigen polysaccharides in Klebsiella pneumoniae. J Biol Chem. 2018; 293: 4666-4679.

[30] Hsieh PF, Wu MC, Yang FL, Chen CT, Lou TC, Chen YY, et al. D-galactan II is an immunodominant antigen in O1 lipopolysaccharide and affects virulence in Klebsiella pneumoniae: implication in vaccine design. Front Microbiol. 2014; 5: 608.

[31] Hernando-Amado S, Laborda P, Martínez JL. Tackling antibiotic resistance by inducing transient and robust collateral sensitivity. Nat Commun. 2023; 14: 1723.

[32] Imamovic L, Sommer MOA. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med. 2013; 5: 204ra132.

[33] Pál C, Papp B, Lázár V. Collateral sensitivity of antibiotic-resistant microbes. TIM. 2015; 23: 401-407.

[34] Majkowska-Skrobek G, Markwitz P, Sosnowska E, Lood C, Lavigne R, Drulis-Kawa Z. The evolutionary trade-offs in phage-resistant Klebsiella pneumoniae entail cross-phage sensitization and loss of multidrug resistance. Environ Microbiol. 2021; 23: 7723-7740.

[35] Acton L, Pye HV, Thilliez G, Kolenda R, Matthews M, Turner AK, et al. Collateral sensitivity increases the efficacy of a rationally designed bacteriophage combination to control Salmonella enterica. J Virol. 2024; 98: e0147623.

[36] Kelly SD, Ovchinnikova OG, Müller F, Steffen M, Braun M, Sweeney RP, et al. Identification of a second glycoform of the clinically prevalent O1 antigen from Klebsiella pneumoniae. Proc Natl Acad Sci USA. 2023; 120: e2301302120.

[37] Hao G, Shu R, Ding L, Chen X, Miao Y, Wu J, et al. Bacteriophage SRD2021 recognizing capsular polysaccharide shows therapeutic potential in serotype K47 Klebsiella pneumoniae infections. Antibiotics. 2021; 10: 894.

[38] Liu JY, Lin TL, Chiu CY, Hsieh PF, Lin YT, Lai LY, et al. Decolonization of carbapenem-resistant Klebsiella pneumoniae from the intestinal microbiota of model mice by phages targeting two surface structures. Front Microbiol. 2022; 13: 877074.

[39] Maffei E, Shaidullina A, Burkolter M, Heyer Y, Estermann F, Druelle V, et al. Systematic exploration of Escherichia coli phage-host interactions with the BASEL phage collection. PLoS Biol. 2021; 19: e3001424.

[40] Wang C, Wang S, Jing S, Zeng Y, Yang L, Mu Y, et al. Data-driven engineering of phages with tunable capsule tropism for Klebsiella pneumoniae. Adv Sci (Weinh). 2024; 11: e2309972.

[41] Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP. Enumeration of bacteriophages by double agar overlay plaque assay. Methods Mol Biol. 2009; 501: 69-76.

[42] Prjibelski A, Antipov D, Meleshko D, Lapidus A, Korobeynikov A. Using SPAdes de novo assembler. Curr Protoc Bioinformatics. 2020; 70: e102.

[43] Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014; 30: 2068-2069.

[44] Buchfink B, Reuter K, Drost HG. Sensitive protein alignments at tree-of-life scale using DIAMOND. Nat Methods. 2021; 18: 366-368.

[45] Göller PC, Elsener T, Lorgé D, Radulovic N, Bernardi V, Naumann A, et al. Multi-species host range of staphylococcal phages isolated from wastewater. Nat Commun. 2021; 12: 6965.

[46] Paradis E, Schliep K. ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R. Bioinformatics. 2019; 35: 526-528.

[47] Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, et al. Roary: rapid large-scale prokaryote pan genome analysis. Bioinformatics. 2015; 31: 3691-3693.

[48] Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics. 2014; 30: 1312-1313.

[49] Kolmogorov M, Yuan J, Lin Y, Pevzner PA. Assembly of long, error-prone reads using repeat graphs. Nat Biotechnol. 2019; 37: 540-546.

[50] Hu J, Fan J, Sun Z, Liu S. NextPolish: a fast and efficient genome polishing tool for long-read assembly. Bioinformatics. 2020; 36: 2253-2255.

[51] Darling AE, Mau B, Perna NT. progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement. PLoS One. 2010; 5: e11147.

[52] Wang Y, Wang S, Chen W, Song L, Zhang Y, Shen Z, et al. CRISPR-Cas9 and CRISPR-assisted cytidine deaminase enable precise and efficient genome editing in Klebsiella pneumoniae. Appl Environ Microbiol. 2018; 84: e01834-18.

[53] Gan L, Feng Y, Du B, Fu H, Tian Z, Xue G, et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae. Nat Commun. 2023; 14: 3215.

[54] Chen H, Liu H, Gong Y, Dunstan RA, Ma Z, Zhou C, et al. Klebsiella-phage cocktail to broaden the host range and delay bacteriophage resistance both in vitro and in vivo. NPJ Biofilms Microbiomes. 2024; 10: 127.

[55] Gencay YE, Jasinskytė D, Robert C, Semsey S, Martínez V, Petersen AØ, et al. Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice. Nat Biotechnol. 2024; 42: 265-274.

[56] Van Kregten E, Westerdaal NA, Willers JM. New, simple medium for selective recovery of Klebsiella pneumoniae and Klebsiella oxytoca from human feces. J Clin Microbiol. 1984; 20: 936-941.

RIGHTS & PERMISSIONS

2025 The Author(s). mLife published by John Wiley & Sons Australia, Ltd on behalf of Institute of Microbiology, Chinese Academy of Sciences.